Ryan Lingerak

Sept. 6, 2023 8:45 a.m.
School of Medicine E501 Mentor: Bing-Cheng Wang, PhD

Go Back

NATURE | 19 JULY 2018 | VOL 559 | 363

https://www.nature.com/articles/s41586-018-0266-0

https://doi.org/10.1038/s41586-018-0266-0

Arianna Calcinotto¹, Clarissa Spataro¹, Elena Zagato¹, Diletta Di Mitri¹, Veronica Gil², Mateus Crespo², Gaston De Bernardis¹, Marco Losa¹, Michela Mirenda¹, Emiliano Pasquini¹, Andrea Rinaldi¹, Semini Sumanasuriya², Maryou B. Lambros², Antje Neeb2, Roberta Lucianò³, Carlo A. Bravi³, Daniel Nava-Rodrigues², David Dolling², Tommaso Prayer-Galetti⁴, Ana Ferreira², Alberto Briganti³, Antonio Esposito⁵, Simon Barry⁶, Wei Yuan², Adam Sharp², Johann de Bono² & Andrea Alimont^i1,7,8,9*

¹Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. ²The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. ³Division of Oncology, Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. ⁴Department of Urology, University of Padova, Padova, Italy. ⁵Experimental Imaging Center, San Raffaele Scientific Institute, Milan, Italy. ⁶IMED Oncology AstraZeneca, Li Ka Shing Centre, Cambridge, UK. ⁷Università della Svizzera italiana, Faculty of Biomedical Sciences, Lugano, Switzerland. ⁸Faculty of Biology and Medicine, University of Lausanne UNIL, Lausanne, Switzerland. ⁹Department of Medicine, Venetian Institute of Molecular Medicine, University of Padova,Padova, Italy.                            *e-mail: andrea.alimonti@ior.iosi.ch